Ann: Investor Webinar on Acquisition of License for Azer-cel, page-324

It sure sounds as though IMU have cranked up their ambitions significantly. Taking Azer “all the way to market” ………

Imugene has many happy problems for BPs if they still sit on their hands!

Many including myself will look back, and say geez, thanks god we have sufficient cash to say thanks but no thanks… well, $150 million + roughly another $60 million hard cash is beyond a dream for any startup least to say oncology bio startup.

Leslie is very confident yet relaxed at the Precision Biosciences acquisition webinar. IMO the best ever!
Why shouldn’t she and the new COO Dr Glover as the high tech FDA/GMP compliant lab manufacturing facility at Durham confirms it’s real, and proven as the lab has already been manufacturing Azer-cell/allogenic Car-T cells for a phase 1b trial for 84 patients who had relapse after their autogenic CarT therapies.

Yes, we will win the FDA accelerated approval/Orphan Drug Approval . Our newly acquired facility have enough donors to manufacture in-house the allogenic CarT for the imminent Registrational trials.

Since invest in the Imugene science , I have been pinching myself if this real to have a safe , durable and effective cancer cure. Precision Biosciences has given me the answer I believe

salute to you Imugene

Kluck